Updates

February 22, 2021February 22, 2021
Xpovio Open to Advanced Myeloma Patients Outside US via Access Program

People with advanced multiple myeloma and diffuse large B-cell lymphoma (DLBCL) will soon be able to access Xpovio (selinexor) outside the U.S. through a managed access program. ... Read more
February 19, 2021February 19, 2021
C4 Therapeutics Readying to Open Phase 1/2a Trial of CFT7455

C4 Therapeutics is preparing to launch a clinical trial testing its lead investigational therapy CFT7455 in multiple myeloma and other blood cancers. The U.S. Food ... Read more
February 17, 2021February 17, 2021
Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse

People with blood type O are significantly less likely to develop multiple myeloma, but those who do are likely to have more aggressive disease and ... Read more
February 15, 2021February 15, 2021
Darzalex Combos Linked to Stronger Cancer Eradication, Prolonged Survival

Adding Darzalex (daratumumab) to standard regimens for adults with relapsed or refractory multiple myeloma resulted in higher rates of deep and durable responses, according to ... Read more
February 12, 2021February 12, 2021
Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients

The Israeli Ministry of Health has approved Xpovio (selinexor), in combination with the corticosteroid dexamethasone, for the treatment of people with multiple myeloma who have ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

October 30, 2017October 30, 2017

Pomalyst Is More Cost-effective Than Darzalex or Kyprolis for Heavily Treated Myeloma Patients, Study Reports

News

A combination of Pomalyst (pomalidomide) and low-dose dexamethasone is cheaper than either Darzalex (daratumumab) or Kyprolis (carfilzomib) alone as a treatment for relapsed or refractory multiple myeloma (RRMM), a study shows. The research, published in Clinical Therapeutics, is titled “Cost-effectiveness of Pomalidomide, Carfilzomib, and ... Read more

Updates

Xpovio Open to Advanced Myeloma Patients Outside US via Access Program

C4 Therapeutics Readying to Open Phase 1/2a Trial of CFT7455

Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse

Darzalex Combos Linked to Stronger Cancer Eradication, Prolonged Survival

Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients

FDA Clears Way for Clinical Trial of HDP-101

Under-the-skin Velcade Found to Work Better in Farydak Triple Combo

Phase 3 Trial of ATG-010 (Xpovio) for Advanced Myeloma Opens in China

EMA Plans Speedy Review of Cilta-cel, CAR T-cell Therapy for Advanced Myeloma

EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients

Dosing Begins in Phase 1 Trial of CERC-007

Subscribe to our mailing list

Jakafi Plus Steroid Continuing to Treat Multiple Myeloma in Phase 1 Trial

$10M Gift to Open Myeloma Research Center at Ohio State

First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy

Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma

FDA Gives Orphan Drug Status to Potential Multiple Myeloma Immunotherapy

First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo

PT-112 Shows Promise for Heavily Treated Myeloma Patients

MMRF Invests in Indapta’s Natural Killer Cell Therapy to Advance Clinical Trials

FDA Approval Sought for Cilta-cel CAR T-cell Therapy

FDA Approves Xpovio Triple Combo for Previously Treated Myeloma

Bispecific Antibody Shows Early, Promising Responses in Trial

CAR T-cell Therapy Cilta-cel Continues to Show Benefits in Heavily Treated Myeloma Patients

MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma

Roche’s Cevostamab Leads to Durable, Deep Responses in Heavily Pre-Treated Patients

Xpovio Approval Sought for Myeloma Indications in 3 Asian Pacific Markets

Dana-Farber, Quest Diagnostics Studying COVID-19 Prevalence in Myeloma

FDA Lifts Hold on Phase 1 Trial for Car-T-Cell Therapy UCARTCS1A

New $100M Program Aims to Improve Diversity in Clinical Trials

Approval of Injection Darzalex Combo for Advanced Myeloma Sought in US, EU

Myeloma UK Calls for More Data Transparency to Safeguard Patients From COVID-19

Allogene to Present Positive Phase 1 Data for Investigational CAR T-cell Therapy ALLO-715

Pomalyst Is More Cost-effective Than Darzalex or Kyprolis for Heavily Treated Myeloma Patients, Study Reports

Xpovio Open to Advanced Myeloma Patients Outside US via Access Program

C4 Therapeutics Readying to Open Phase 1/2a Trial of CFT7455

Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse

Darzalex Combos Linked to Stronger Cancer Eradication, Prolonged Survival

Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients

FDA Clears Way for Clinical Trial of HDP-101

Under-the-skin Velcade Found to Work Better in Farydak Triple Combo

Phase 3 Trial of ATG-010 (Xpovio) for Advanced Myeloma Opens in China

EMA Plans Speedy Review of Cilta-cel, CAR T-cell Therapy for Advanced Myeloma

EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients

Dosing Begins in Phase 1 Trial of CERC-007

Subscribe to our mailing list

Jakafi Plus Steroid Continuing to Treat Multiple Myeloma in Phase 1 Trial

$10M Gift to Open Myeloma Research Center at Ohio State

First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy

Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma

FDA Gives Orphan Drug Status to Potential Multiple Myeloma Immunotherapy

First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo

PT-112 Shows Promise for Heavily Treated Myeloma Patients

MMRF Invests in Indapta’s Natural Killer Cell Therapy to Advance Clinical Trials

FDA Approval Sought for Cilta-cel CAR T-cell Therapy

FDA Approves Xpovio Triple Combo for Previously Treated Myeloma

Bispecific Antibody Shows Early, Promising Responses in Trial

CAR T-cell Therapy Cilta-cel Continues to Show Benefits in Heavily Treated Myeloma Patients

MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma

Roche’s Cevostamab Leads to Durable, Deep Responses in Heavily Pre-Treated Patients

Xpovio Approval Sought for Myeloma Indications in 3 Asian Pacific Markets

Dana-Farber, Quest Diagnostics Studying COVID-19 Prevalence in Myeloma

FDA Lifts Hold on Phase 1 Trial for Car-T-Cell Therapy UCARTCS1A

China Approves Xgeva to Prevent Bone Events Due to Multiple Myeloma, Other Cancers

New $100M Program Aims to Improve Diversity in Clinical Trials

Approval of Injection Darzalex Combo for Advanced Myeloma Sought in US, EU

Myeloma UK Calls for More Data Transparency to Safeguard Patients From COVID-19

Allogene to Present Positive Phase 1 Data for Investigational CAR T-cell Therapy ALLO-715

Pomalyst Is More Cost-effective Than Darzalex or Kyprolis for Heavily Treated Myeloma Patients, Study Reports